Success Beyond Game Day and XPE Integrate AI Mindset Training into SHREDmill Platform

Success Beyond Game Day and SHREDmill have partnered to integrate AI-driven mindset training into XPE’s SHREDmill platform and online community. This collaboration seeks to elevate the overall development of athletes by incorporating advanced mental training into their speed training programs,…

Read MoreSuccess Beyond Game Day and XPE Integrate AI Mindset Training into SHREDmill Platform

Quince Therapeutics Announces ATTeST Trial Data Publication in The Lancet Neurology

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on utilizing patients’ own biology to treat rare diseases, has announced the online publication of data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial in…

Read MoreQuince Therapeutics Announces ATTeST Trial Data Publication in The Lancet Neurology

Concentra Expands Telemedicine to Include Behavioral Health for Workers’ Comp

Concentra®, a leading provider of occupational medicine, has announced the introduction of its new behavioral health service on Concentra Telemed®, the company’s telemedicine platform for workers’ compensation. Concentra® has introduced a behavioral health service to its Concentra Telemed® platform, enhancing…

Read MoreConcentra Expands Telemedicine to Include Behavioral Health for Workers’ Comp

KalVista’s Sebetralstat Approved by EMA for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for the on-demand treatment of hereditary angioedema (HAE). The application will…

Read MoreKalVista’s Sebetralstat Approved by EMA for Hereditary Angioedema